Loading…
ArriVent BioPharma, Inc. is projected to rise to $44.94 by 2027, a +33% move from its current price of $33.69. AVBP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $32.91 | $33.70 | $34.51 | +0.03% |
| Jul 13 | $32.60 | $33.71 | $34.86 | +0.07% |
| Jul 14 | $32.36 | $33.72 | $35.14 | +0.10% |
| Jul 15 | $32.17 | $33.74 | $35.38 | +0.13% |
| Jul 16 | $32.00 | $33.75 | $35.59 | +0.17% |
| Jul 17 | $31.85 | $33.76 | $35.78 | +0.20% |
| Jul 18 | $31.71 | $33.77 | $35.96 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $31.71 | $33.77 | $35.96 | +0.23% |
| Week 2 | $30.97 | $33.85 | $37.00 | +0.47% |
| Week 3 | $30.43 | $33.93 | $37.83 | +0.71% |
| Week 4 | $29.99 | $34.01 | $38.56 | +0.94% |
| Week 5 | $29.62 | $34.09 | $39.23 | +1.18% |
| Week 6 | $29.29 | $34.17 | $39.86 | +1.42% |
| Week 7 | $29.00 | $34.25 | $40.45 | +1.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for the unmet medical needs of patients with cancers. Its lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd.
ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
ArriVent BioPharma, Inc. trades as AVBP in the healthcare sector and has a current price of $32.70 with a market capitalization of $1.52B, ranking 2106. The stock sits in the Healthcare category, reflecting its focus on cancer therapies and related medicines.
The long-range price outlook shows a path of rising value over the forecast horizon, starting near the current level and moving higher into 2030 and beyond, with a sequence of annual targets and bullish sentiment emerging after 2026.
A major floor 37.6% below — a decisive break under it would weaken the trend.
The nearest floor, 19.9% below — buyers have tended to step in here.
The nearest ceiling, 3.1% above — a clean break opens room to run.
A major ceiling 17.5% above — clearing it would confirm fresh momentum.
Key AVBP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AVBP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $33.89 | Sell | $33.83 | Sell |
| MA 10 | $34.17 | Sell | $33.73 | Sell |
| MA 20 | $32.92 | Buy | $32.99 | Buy |
| MA 50 | $30.66 | Buy | $30.98 | Buy |
| MA 100 | $27.92 | Buy | $28.64 | Buy |
| MA 200 | $24.43 | Buy | $26.11 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.38 | Neutral |
| Stoch RSI (14) | 12.91 | Buy |
| CCI (20) | 36.01 | Neutral |
| Williams %R (14) | -38.60 | Info |
| MACD (12,26,9) | -0.12 | Sell |
| ROC (12) | -0.15 | Sell |
| Bollinger %B (20,2) | 0.62 | Neutral |
| Stochastic %K (14) | 61.40 | Neutral |
| TRIX (15) | 0.57 | Buy |
| Awesome (5,34) | 2.41 | Buy |
| Ultimate (7,14,28) | 39.42 | Neutral |
| Momentum (10) | -0.14 | Sell |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 33.45 | Buy |
| ADX (14) | 21.70 | Buy |
| ATR (14) | 0.57 | Info |
The 30-day technical picture is bullish. RSI14 is 60, suggesting continued upward momentum with potential for further gains. The stock is trading above the SMA50 of $29.51 and well above the SMA200 of $23.46, indicating positive near-term price dynamics.
A key near-term framework places support at $26.15 and resistance at $33.09, with a 30-day range between $26.91 and $39.73 and an annualized volatility of 60%. These factors point to a constructive setup for the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.93 | $33.69 | $44.88 | 0% | Neutral | |
| $36.20 | $44.94 | $58.73 | +33% | Bullish | |
| $38.90 | $49.45 | $66.79 | +47% | Bullish | |
| $50.75 | $65.80 | $91.19 | +95% | Bullish | |
| $66.52 | $87.76 | $124.29 | +161% | Bullish | |
| $73.18 | $98.10 | $141.59 | +191% | Bullish | |
| $84.22 | $114.56 | $168.20 | +240% | Bullish | |
| $91.33 | $125.95 | $187.81 | +274% | Bullish | |
| $97.33 | $135.98 | $205.68 | +304% | Bullish | |
| $112.94 | $159.76 | $244.88 | +374% | Bullish | |
| $186.77 | $279.43 | $452.89 | +729% | Bullish | |
| $393.43 | $647.21 | $1,138.52 | +18.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $18.93 | $33.69 | $39.54 | +0.00% |
| August 2026 | $28.53 | $33.57 | $40.47 | -0.36% |
| September 2026 | $29.35 | $34.74 | $42.28 | +3.48% |
| October 2026 | $29.39 | $34.96 | $42.90 | +0.64% |
| November 2026 | $29.20 | $34.89 | $43.11 | -0.21% |
| December 2026 | $30.08 | $36.09 | $44.88 | +3.45% |
Click any year to see its month-by-month AVBP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The AVBP price prediction for 2026 points to an average of $33.69 (low $18.93, high $44.88) — a potential gain of 0% on today's $33.69. Price action looks broadly range-bound.
In 2027, AVBP is projected to trade between $36.20 and $58.73, averaging $44.94 — a potential gain of +33% from today's $33.69. That is up +33% on the projected 2026 average. Buyers look set to stay in control over this stretch.
ArriVent BioPharma, Inc.'s 2028 outlook centres on $49.45, within a $38.90 to $66.79 range. That is up +10% on the projected 2027 average. That marks a +47% change versus current levels. Momentum favours further upside here.
By 2029, AVBP could reach as high as $91.19, with a base case around $65.80 and support toward $50.75 — roughly +95% from $33.69. Buyers look set to stay in control over this stretch.
Expect AVBP to range from $66.52 to $124.29 through 2030. The $87.76 average target implies a +161% move from current prices. That is up +33% on the projected 2029 average. Momentum favours further upside here.
The AVBP price prediction for 2031 points to an average of $98.10 (low $73.18, high $141.59) — a potential gain of +191% on today's $33.69. Buyers look set to stay in control over this stretch.
In 2032, AVBP is projected to trade between $84.22 and $168.20, averaging $114.56 — a potential gain of +240% from today's $33.69. That is up +17% on the projected 2031 average. Momentum favours further upside here.
ArriVent BioPharma, Inc.'s 2033 outlook centres on $125.95, within a $91.33 to $187.81 range. That is up +10% on the projected 2032 average. That marks a +274% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, AVBP could reach as high as $205.68, with a base case around $135.98 and support toward $97.33 — roughly +304% from $33.69. Momentum favours further upside here.
Expect AVBP to range from $112.94 to $244.88 through 2035. The $159.76 average target implies a +374% move from current prices. That is up +17% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The AVBP price prediction for 2040 points to an average of $279.43 (low $186.77, high $452.89) — a potential gain of +729% on today's $33.69. Momentum favours further upside here.
In 2050, AVBP is projected to trade between $393.43 and $1,138.52, averaging $647.21 — a potential gain of +18.2x from today's $33.69. That is up +132% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AVBP today (≈ 29.682398 AVBP) could be worth
$19,210.69
+$18,210.69 (+1821%) by 2050 · US Dollar
Based on the average projected AVBP price of $647.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AVBPwould be worth at today's price.
$1,000 invested in AVBP on Jul 10, 2025 (≈ 45.392645 AVBP) would be worth
$1,529.28
+$529.28 (+52.9%) today · 1.53× · US Dollar
Based on a AVBP entry price of $22.03 vs. today's $33.69.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $34.67 | $971.73 | -2.8% |
| 1 month ago | $30.49 | $1,104.95 | +10.5% |
| 3 months ago | $25.46 | $1,323.25 | +32.3% |
| 6 months ago | $20.44 | $1,648.24 | +64.8% |
| 1 year ago | $22.03 | $1,529.28 | +52.9% |
| All time (2.5y) ago | $20 | $1,684.5 | +68.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AVBP forecast.
Our base-case forecast reaches $67.00 around 2030.
Implied market cap at $67.00: $3.12B
The multi-year forecast shows a clear upside trajectory with gradually higher price targets and strong longer-run upside. In 2026 the avg is $32.70 with a neutral sentiment; by 2027 the avg rises to $42.87 and the max to $57.70 (ROI 31.1%), and by 2028 the avg is $47.59 (ROI 45.5%). The projection strengthens further for 2029 with an avg of $66.56 (ROI 103.5%), and 2030 with an avg of $88.48 (ROI 170.6%).
The forecast continues to climb to 2040 with an avg of $279.37 (ROI 754.4%) and reaches 2050 with an avg of $671.41 (ROI 1953.3%), with a max of $1,279.35. Across this horizon, sentiment remains bullish from 2027 onward, reflecting expected upside potential.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $88.48 with a range from $64.58 to $130.97 and a projected ROI of 170.6%.
The forecast indicates rising averages from 2027 onward (e.g., 2027 avg $42.87, 2028 avg $47.59, 2029 avg $66.56, 2030 avg $88.48) with substantial upside by 2040 ($279.37) and 2050 ($671.41). These are estimates, not guarantees.
Yes—the maximum forecast for 2050 is $1,279.35.
Current price is $32.70 and market cap is $1.52B.
The 2040 forecast shows an average price of $279.37 with a range from $172.93 to $484.35 and a ROI of 754.4%.
ArriVent BioPharma, Inc. Community Discussion
0Share your ArriVent BioPharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.